Two key patents for Tutivia™ and Clarava™ granted in the United States

Intellectual property portfolio strengthened

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has been granted two key patents in the United States that support and protect the Company’s core technologies in RNA signature biomarker tests used for assessment of the prognostic risk pre-transplant (Clarava™) and post- transplant (Tutivia™) of acute kidney transplant rejection.

The patents cover broad molecular methods for predicting and diagnosing subclinical and clinical acute rejection, both pre- and post- kidney transplant by algorithmic analysis of gene sets and underpin both of Verici Dx’s lead products, TutiviaTM and ClaravaTM, and provide protection until 2036 and 2039 respectively. The patents underpinning TutiviaTM have also been previously granted in Europe, China and Australia.

These products use a weighted pattern of RNA biomarkers (signature) to assess the risk of rejection by the kidney transplant recipient and to assess rejection earlier and more reliably than other currently available methods. Verici Dx continues to file additional patents reflecting novel refinements to its predictive RNA signatures and methodologies driven by advanced machine learning techniques.

The protection of the Company’s intellectual property is fundamental to its strategy of amassing full transcriptomic data from the biological systems and interactions associated with transplant rejection and, over the longer term, informing transplant analysis in other organs and in the broader field of immune-mediated diseases.

Sara Barrington, CEO of Verici Dx, said:
“ClaravaTM and TutiviaTM address a significant unmet need and seek to improve outcomes for kidney transplant patients, by providing early, actionable information for clinicians to inform treatment plans. These significant new patents bolster our intellectual property portfolio and protect our proprietary methods of predicting and diagnosing sub-clinical and clinical acute kidney rejection.”



Sara Barrington, CEO
Julian Baines, Chairman
Via Walbrook PR

N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus / Sam Allen

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07748 651 727

About Verici Dx plc

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.